Streetbeat News

SAVA

Cassava Sciences, Inc.

https://www.cassavasciences.com

Industry

Biotechnology

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Open

26.40

Mkt cap

1.2B

Volume

1.6M

High

27.16

P/E Ratio

-8.95

52-wk high

42.20

Low

24.65

Div yield

N/A

52-wk low

8.79

Market whales have taken a significant interest in Cassava Sciences (NASDAQ:SAVA) options, with a mix of bullish and bearish sentiments. The options activity suggests a price range of $20.0 to $40.0. Cassava Sciences is currently trading at $27.58, down by 21.38%, with an anticipated earnings release in 2 days.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 5:45 pm

Cassava Sciences, Inc. (NASDAQ:SAVA) shares are trading higher due to an upcoming conference call, extended trials for simufilam, and the passing of a long-time board member. Analysts expect an EPS loss of 40 cents.

Portfolio Pulse from Vaishali Prayag

August 05, 2024 | 7:44 pm

Cassava Sciences, Inc. (NASDAQ:SAVA) saw its stock price surge by 24.4% to $29.21, driven by rising short interest and an upcoming conference call. The company has a high short percent of float at 35.89%, and it would take traders 4.75 days to cover their short positions. Cassava plans to extend its open-label extension trials for simufilam by up to 36 months.

Portfolio Pulse from Vaishali Prayag

August 02, 2024 | 7:52 pm

Cassava Sciences (NYSE:SAVA) has seen a 23.21% increase in its short percent of float, now at 35.89%. This indicates a bearish sentiment among investors. It would take traders 4.75 days to cover their short positions. Compared to its peers, Cassava Sciences has a significantly higher short interest.

Portfolio Pulse from Benzinga Insights

August 02, 2024 | 4:15 pm

In July, small-cap stocks outperformed large-cap stocks, with Serve Robotics Inc (NASDAQ:SERV) leading the pack with an 803% increase. Other notable performers included CommScope Holding Company Inc (NASDAQ:COMM), Hawaiian Electric Industries, Inc. (NYSE:HE), and Q32 Bio Inc (NASDAQ:QTTB). The iShares Russell 2000 ETF (NYSE:IWM) rose by over 11%, indicating a shift from large caps to small caps.

Portfolio Pulse from Hayden Buckfire

August 01, 2024 | 8:54 pm

Cassava Sciences, Inc. (NASDAQ:SAVA) saw a significant stock price increase after announcing an extension of its open-label extension trials for its Alzheimer's treatment, simufilam. The extension aims to provide continuous treatment for patients and gather more long-term data. The company is also conducting two major Phase 3 studies, with results expected in 2024 and 2025.

Portfolio Pulse from Vaishali Prayag

July 31, 2024 | 9:01 pm

U.S. stocks saw significant gains on Wednesday, with the Dow Jones index rising over 200 points. Match Group, Inc. (NASDAQ:MTCH) led the surge with a 15% increase following better-than-expected Q2 revenue and strong Q3 guidance. Other notable gainers included Powell Industries, Inc. (NASDAQ:POWL), Stardust Power Inc. (NASDAQ:SDST), Modine Manufacturing Company (NYSE:MOD), and several others, all reporting better-than-expected financial results.

Portfolio Pulse from Avi Kapoor

July 31, 2024 | 5:05 pm

Cassava Sciences (NASDAQ:SAVA) announced an extension of its open-label extension trials for simufilam in Alzheimer's disease by up to 36 months. This allows participants to continue treatment pending the results of ongoing Phase 3 trials. The company will also add cognition and plasma biomarker monitoring to gather additional long-term data.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 12:19 pm

Cassava Sciences (NASDAQ:SAVA) has significantly outperformed the market over the past 5 years, delivering an average annual return of 56.63%. A $1000 investment in SAVA 5 years ago would be worth $9,083.94 today. The article highlights the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

July 23, 2024 | 4:30 pm

Cassava Sciences Inc (NASDAQ:SAVA) is advancing its Alzheimer's drug, simufilam, through Phase 3 trials. The trials are crucial for determining the drug's efficacy and safety, with results expected by December 2024 and June 2025. The company faces ongoing investigations by the DOJ and SEC, and the credibility of its clinical trial results has been questioned by the FDA.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 6:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.